TheraRadar

Otonomy

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 3/22/2021

22
Total Trials
10
Phase 3
10
Phase 2
0
Recruiting
242
Score

Pipeline by Phase

Phase 3
10
Phase 2
10
Phase 1
4

Therapeutic Focus

Meniere's Disease Acute Otitis Media AOMT Otitis Media With Effusion Subjective Tinnitus

Clinical Trials (22)

NCT02768662 Phase 3 TERMINATED

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Started: 8/1/2016

NCT02717442 Phase 3 TERMINATED

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Started: 3/21/2016

NCT02612337 Phase 3 COMPLETED

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Started: 10/27/2015

NCT02706730 Phase 3 TERMINATED

A 6-Month Extension Study of OTO-104 in Meniere's Disease

Started: 2/1/2016

NCT03664674 Phase 3 COMPLETED

Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Started: 8/27/2018

NCT02600559 Phase 3 COMPLETED

Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes

Started: 10/1/2015

NCT02350998 Phase 3 COMPLETED

Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration

Started: 1/1/2015

NCT02801370 Phase 3 COMPLETED

Phase 3 Study of OTO-201 in Acute Otitis Externa

Started: 6/1/2016

NCT01949155 Phase 3 COMPLETED

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Started: 11/1/2013

NCT01949142 Phase 3 COMPLETED

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Started: 11/1/2013

NCT04829214 Phase 2 COMPLETED

OTO-313 in Subjects With Unilateral Subjective Tinnitus

Started: 3/22/2021

NCT02719158 Phase 2 COMPLETED

Dose Ranging Study of OTO-201 in AOMT

Started: 2/1/2016

NCT02408796 Phase 2 COMPLETED

Open-Label Study of OTO-201 for Treatment of AOMT

Started: 3/1/2015

NCT02511561 Phase 2 COMPLETED

OTO-201 for the Treatment of Otitis Externa

Started: 7/1/2015

NCT02997189 Phase 2 TERMINATED

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Started: 11/15/2016

NCT02740387 Phase 2 TERMINATED

Open Label Study of OTO-104 in Subjects With Meniere's Disease

Started: 6/1/2016

NCT02265393 Phase 2 COMPLETED

A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom

Started: 10/1/2014

NCT01412177 Phase 2 COMPLETED

OTO-104 for the Treatment of Meniere's Disease

Started: 11/1/2013

NCT03918109 Phase 1 COMPLETED

OTO-313 in Subjects With Subjective Tinnitus

Started: 4/4/2019

NCT04129775 Phase 1 COMPLETED

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

Started: 10/1/2019

NCT01755286 Phase 1 COMPLETED

OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Started: 12/1/2012

NCT01084525 Phase 1 COMPLETED

OTO-104 for Meniere's Disease

Started: 3/1/2010

Drug Candidates

OTO-104 OTO-313 OTO-413 OTO-201 (ciprofloxacin) OTO-201 OTO-104 (steroid) 3 mg OTO-104 (steroid) 12 mg
Activity Status: Inactive
Last Trial Started: 3/22/2021
Last Trial Ended: 9/5/2022
Trials (12 months): 0
Completed Trials: 17
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.